Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00004227 · ClinicalTrials.gov registry record · Phase 3
Radiation Therapy With or Without Cetuximab in Treating Patients With Stage III or Stage IV Cancer of the Oropharynx, Hypopharynx, or Larynx
A Phase 3 study, sponsored by University of Alabama at Birmingham.
- Terminated
- Registry status
- Phase 3
- Development phase
- 32
- Enrollment target
NCT00004227 is a Phase 3 study that was terminated before completion, run by University of Alabama at Birmingham. The registered enrollment target is 32 participants.
The verdict
NCT00004227, a Phase 3 study, was terminated before completion, sponsored by University of Alabama at Birmingham.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 32 participants
- Enrollment target
Study Summary
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Monoclonal antibodies such as cetuximab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. It is not yet known if radiation therapy is more effective with or without cetuximab for cancer of the oropharynx, hypopharynx, or larynx. PURPOSE: Randomized phase III trial to compare the effectiveness of radiation therapy with or without cetuximab in treating patients who have stage III or stage IV cancer of the oropharynx, hypopharynx, or larynx.
Interventions
- BIOLOGICAL cetuximab
- PROCEDURE conventional surgery
- RADIATION radiation therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 1999-04 |
| Est. Completion | 2008-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00004227
The ClinicalTrials.gov registry entry for NCT00004227 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Alabama at Birmingham, which has 1,160 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which cetuximab is the first listed.
NCT00004227 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00004227 about?
NCT00004227 is a clinical study titled "Radiation Therapy With or Without Cetuximab in Treating Patients With Stage III or Stage IV Cancer of the Oropharynx, Hypopharynx, or Larynx". RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Monoclonal antibodies such as cetuximab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. It is not yet known if radiation therapy is more effective with or...
What is the current status of trial NCT00004227?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 32 participants. The study started on 1999-04. Estimated completion is 2008-05.
What interventions are being tested in trial NCT00004227?
The interventions under investigation include: cetuximab (BIOLOGICAL), conventional surgery (PROCEDURE), radiation therapy (RADIATION).
Who is sponsoring clinical trial NCT00004227?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.